Skip to main content
. 2019 Apr 14;11(4):180. doi: 10.3390/pharmaceutics11040180

Figure 6.

Figure 6

In vivo wound healing assay in mouse model. (A) Wound Healing in Diabetic C57/BL6 Mice after Treatment with Various Electrospun Nanofibrous Scaffolds (Batch 1) [a–t represent the extent of wound healing during 12 days period] Group 1—No treatment (negative control); Group 2—0.1% gentamicin sulfate ointment (positive control); Group 3—PLGA/Gelatin 70:30 scaffold without gentamicin sulfate and rhEGF; Group 4—PLGA/Gelatin 70:30 scaffold with gentamicin sulfate and rhEGF; Group 5—PLGA/Gelatin 70:30 scaffold with gentamicin sulfate and without rhEGF. (B) Open wound area (% of initial area) over 12 days for each treatment group from control and three experimental groups performed from five different wound healing assays. The results are expressed as the median ± standard deviation from five independent experiments performed in triplicate (n = 5).